Company profile: Paion
1.1 - Company Overview
Company description
- Provider of biopharmaceutical products; develops and commercializes drug candidates for diseases or interventions with substantial unmet medical need. Lead compound: remimazolam, an intravenous, ultra-short-acting, controllable benzodiazepine. Portfolio: Byfavo (procedural sedation, general anesthesia); Angiotensin II/GIAPREZA (refractory hypotension in septic or distributive shock); Eravacycline/XERAVA (complicated intra-abdominal infections in adults).
Products and services
- Byfavo: A clinical-grade intravenous, ultra-short-acting, controllable benzodiazepine sedative/anesthetic approved for procedural sedation and general anesthesia in various regions
- Eravacycline (XERAVA): A novel fluorocycline antibiotic engineered for the treatment of complicated intra-abdominal infections in adult patients
- Angiotensin II (GIAPREZA): A clinical-grade vasoconstrictor for the treatment of refractory hypotension in adults with septic or other distributive shock
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Paion
Athersys
HQ: United States
Website
- Description: Provider of an adult-derived, off-the-shelf stem cell therapy platform, MultiStem, for neurological, inflammatory and immune, cardiovascular, and other critical care indications. Conducts clinical trials and programs including MASTERS-2 and TREASURE for stroke, and AMI, PVD, and congestive heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Athersys company profile →
Innovation Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies addressing unmet medical needs, developing Brilacidin, a small-molecule drug candidate with immunomodulatory, anti-inflammatory, and antimicrobial properties tested for COVID-19, oral mucositis, inflammatory bowel disease, serious skin infections, and fungal diseases; and BEAMED, an image-guided surgical laser platform under development for treating cancer and epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innovation Pharmaceuticals company profile →
Paladin Labs
HQ: Canada
Website
- Description: Provider of innovative pharmaceutical products, headquartered in Montreal, Canada, specializing in researching, developing, acquiring, and in-licensing for the Canadian and world markets, supported by a focused national sales team and proven marketing expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Paladin Labs company profile →
Dyax
HQ: United States
Website
- Description: Provider of biotherapeutics focused on the discovery, development and commercialization for unmet medical needs, with an emphasis on inflammatory and oncology indications; lead product DX-88 approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dyax company profile →
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Paion
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Paion
2.2 - Growth funds investing in similar companies to Paion
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Paion
4.2 - Public trading comparable groups for Paion
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →